Sujatha Gurunathan

clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Phase 2 Study of Oral Ifetroban in Individuals with DMD

By Sujatha Gurunathan | August 10, 2022
Blog Post

Simply Stated: What is Myasthenia Gravis (MG)?

By Sujatha Gurunathan | June 27, 2022
Blog Post

Eledon Announces Positive Topline Results from a Phase 2a Study of Tegoprubart to Treat ALS

By Sujatha Gurunathan | June 1, 2022
FRDA
Blog Post

Simply Stated: What is Friedreich’s Ataxia (FRDA)?

By Sujatha Gurunathan | May 31, 2022
Blog Post

Research Study Alert: Track-ALS Study of Home-Based Digital Monitoring to Assess ALS Progression

By Sujatha Gurunathan | May 23, 2022
Blog Post

Clinical Trial Alert: Phase 3 Study of investigational drug in Adults Living with ALS

By Sujatha Gurunathan | May 17, 2022
RADICAVA ORS
Blog Post

FDA Approves MTPA’s RADICAVA ORS for Treatment of ALS

By Sujatha Gurunathan | May 13, 2022
muscular dystrophy survey
Blog Post

Research Study Alert: Study of Wearable Gait Sensor in People with or without Neuromuscular Disease

By Sujatha Gurunathan | May 2, 2022

FDA Approves Alexion’s Ultomiris for Treatment of gMG

By Sujatha Gurunathan | April 28, 2022
Blog Post

Simply Stated: Inclusion Body Myositis, Revisited

By Sujatha Gurunathan | April 27, 2022